Effects of thyroid hormone on bone

Clinical Reviews in Bone and Mineral Metabolism

Volumn 2, Issue 2, 2004, Pages 135-150

  Stathatos, Nikolaos ^a   Wartofsky, Leonard ^a  

^a WASHINGTON HOSPITAL CENTER   (United States)

Author keywords

Bone; Bone density; Osteoporosis; Thyroid hormone; Thyroxine

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; THYROID HORMONE; THYROID HORMONE RECEPTOR; THYROTROPIN;

BONE METABOLISM; BONE MINERAL; CARDIOTOXICITY; DISEASE ASSOCIATION; DOSE CALCULATION; FEMALE; FRACTURE; HUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; RETROSPECTIVE STUDY; REVIEW; RISK ASSESSMENT; RISK FACTOR; THYROID HORMONE BLOOD LEVEL; THYROTOXICOSIS;

EID: 4143114897     PISSN: 15348644     EISSN: None     Source Type: Journal    
DOI: 10.1385/BMM:2:2:135     Document Type: Review

References (69)

1. Abu EO, Bord S, Homer A, Chatterjee VK, Compston JE. 1997 The expression of thyroid hormone receptors in human bone. Bone 21:137-142.
2. Harvey RD, McHardy KC, Reid IW, et al. 1991 Measurement of bone collagen degradation in hyperthyroidism and during thyroxine replacement therapy using pyridinium cross-links as specific urinary markers. J Clin Endocrinol Metab 72:1189-1194.
3. Freitas, F.R., et al., Spared bone mass in rats treated with thyroid hormone receptor TR beta-selective compound GC-1. Am J Physiol Endocrinol Metab, 2003. 285(5):E1135-41.
4. 3R alpha gene encoding a thyroid hormone receptor is essential for post-natal development and thyroid hormone production. Endo J 16:4412-4420.
5. Gauthier K, Plateroti M, Harvey CB, et al. 2001 Genetic analysis reveals different functions for the products of the thyroid hormone receptor alpha locus. Mol Cell Biol 21:4748-4760.
6. Abe E, Marians RC, Yu W, et al. 2003 TSH is a negative regulator of skeletal remodeling, Cell 115:151-162.
7. Ettinger B, Wingerd J. 1982 Thyroid supplements: effect on bone mass. West J Med 136:473-476.
8. Fallon MD, Perry HM 3rd, Bergfeld M, Droke D, Teitelbaum SL, Avioli LV. 1983 Exogenous hyperthyroidism with osteoporosis. Arch Intern Med 143:442-444.
9. Coindre JM, David JP, Riviere L, et al. 1986 Bone loss in hypothyroidism with hormone replacement. A histomorphometric study. Arch Intern Med 146:48-53.
10. Ross DS, Neer RM, Ridgway EC, Daniels GH. 1987 Subclinical hyperthyroidism and reduced BMD as a possible result of prolonged suppression of the pituitary-thyroid axis with L-thyroxine. Am J Med 82:1167-1170.
11. Paul LT, Kerrigan J, Kelly AM, Braverman LE, Baran DT. 1988 Long-term L-thyroxine therapy is associated with decreased hip BMD in premenopausal women. JAMA 259:3137-3141.
12. Taelman P, Kaufman JM, Janssens X, Vandecauter H, Vermeulen A. 1990 Reduced forearm bone mineral content and biochemical evidence of increased bone turnover in women with euthyroid goitre treated with thyroid hormone. Clin Endocrinol (Oxf)33:107-117.
13. Stall GM, Harris S, Sokoll LJ, Dawson-Hughes B. 1990 Accelerated bone loss in hypothyroid patients overtreated with L-thyroxine. Ann Intern Med 113:265-269.
14. Toh SH, Brown PH. 1990 Bone mineral content in hypothyroid male patients with hormone replacement: a 3-year study. J Bone Miner Res 5:463-467.
15. Ribot C, Tremollieres F, Pouilles JM, Louvet JP. 1990 BMD and thyroid hormone therapy. Clin Endocrinol (Oxf) 33:143-153.
16. Ross DS. 1993 BMD is not reduced during the short-term administration of levothyroxine to postmenopausal women with subclinical hypothyroidism: a randomized, prospective study. Am J Med 95:385-388.
17. Vestergaard P, Weeke J, Hoeck HC, et al. 2000 Fractures in patients with primary idiopathic hypothyroidism. Thyroid 10:335-340.
18. Sabuncu T, Aksoy N, Arikan E, Ugur B, Tasan E, Hatemi H. 2001 Early changes in parameters of bone and mineral metabolism during therapy for hyper- and hypothyroidism. Endocr Res 27:203-213.
19. Faber J, Perrild H, Johansen JS. 1991 Serum bone Gla protein (BGP) during treatment of hyperthyroidism and hypothyroidism. A longitudinal study. Horm Metab Res 23:135-138.
20. Diamond T, Nery L. Hales I. 1991 A therapeutic dilemma: suppressive doses of thyroxine significantly reduce bone mineral measurements in both premenopausal and postmenopausal women with thyroid carcinoma. J Clin Endocrinol Metab 72:1184-1188.
21. Lakatos P Hollo I, Horvath C. 1986 Severe postmenopausal osteoporosis and thyroid hormones. Arch Intern Med 146:1859.
22. Langdahl BL, Loft AG, Moller N, et al. 1997 Is skeletal responsiveness to thyroid hormone altered in primary osteoporosis or following estrogen replacement therapy? J Bone Miner Res 12:78-88.
23. Jodar E, Munoz-Torres M, Escobar-Jiminez F, Quesada-Charneco M, Lund del Castillo JD. 1997 Bone loss in hyperthyroid patients and in former hyperthyroid patients controlled on medical therapy: influence of aetiology and menopause. Clin Endocrinol (Oxf) 47:279-285.
24. Adlin EV, Maurer AH, Marks AD, Channick BJ. 1991 BMD in postmenopausal women treated with L-thyroxine. Am J Med 90:360-366.
25. Hurley DL, Tiegs RD, Wahner HW, Heath H 3rd. 1987 Axial and appendicular BMD in patients with long-term deficiency or excess of calcitonin. N Engl J Med 317:537-541.
26. Gonzalez DC, Mautalen CA, Correa PH, el Tamer E, el Tamer S. 1991 Bone mass in totally thyroidectomized patients. Role of calcitonin deficiency and exogenous thyroid treatment. Acta Endocrinol (Copenh) 124:521-525.
27. McDermott MT, Kidd GS, Blue P, Ghaed V, Hofeldt FD. 1983 Reduced bone mineral content in totally thyroidectomized patients: possible effect of calcitonin deficiency. J Clin Endocrinol Metab 56:936-939.
28. Kung AW, Pun KK. 1991 BMD in premenopausal women receiving long-term physiological doses of levothyroxine. JAMA 265:2688-2691.
29. Gam AN, Jensen GF, Hasselstrom K, Olsen M, Nielsen KS. 1991 Effect of thyroxine therapy on bone metabolism in substituted hypothyroid patients with normal or suppressed levels of TSH. J Endocrinol Invest 14:451-455.
30. Franklyn JA, Betteridge J, Daykin J. 1992 Long-term thyroxine treatment and BMD. Lancet, 1992. 340(8810):9-13.
31. Solomon BL, Wartofsky L, Burman KD. 1993 Prevalence of fractures in postmenopausal women with thyroid disease. Thyroid 3:17-23.
32. Langdahl BL, Loft AG, Eriksen EF, Mosekilde L, Charles P. 1996 Bone mass, bone turnover and body composition in former hypothyroid patients receiving replacement therapy. Eur J Endocrinol 134:702-709.
33. Langdahl BL, Loft AG, Eriksen EF, Mosekilde L, Charles P. 1996 Bone mass, bone turnover, body composition, and calcium homeostasis in former hyperthyroid patients treated by combined medical therapy. Thyroid 6:161-168.
34. Langdahl BL, Loft AG, Eriksen EF, Mosekilde L, Charles P. 1996 Bone mass, bone turnover, calcium homeostasis, and body composition in surgically and radioiodine-treated former hyperthyroid patients. Thyroid 6:169-175.
35. Duncan WE, Chng A, Solomon B, Wartofsky L. 1994 Influence of clinical characteristics and parameters associated with thyroid hormone therapy on the BMD of women treated with thyroid hormone. Thyroid 4:183-190.
36. Leger J, Ruiz JC, Guibourdenche J, Kindermans C, Garabedian M, Czernichow P. 1997 Bone mineral density and metabolism in children with congenital hypothyroidism after prolonged L-thyroxine therapy. Acta Paediatr 86:704-710.
37. Vestergaard P, Rejnmark L, Weeke J, Mosekilde L. 2000 Fracture risk in patients treated for hyperthyroidism. Thyroid 10:341-348.
38. Hadji P, Hars O, Sturm G, Bauer T, Emons G, Schulz KD. 2000 The effect of long-term, non-suppressive levothyroxine treatment on quantitative ultrasonometry of bone in women. Eur J Endocrinol 142:445-450.
39. Sugino K, Kure Y, Ozaki O, Ito K, Matsomoto A. 1992 [Does L-thyroxine administration in a dose to suppress TSH secretion induce metabolic bone disturbance in patients with thyroid carcinoma?]. Nippon Geka Gakkai Zasshi 93:753-756.
40. Stepan JJ Limanova Z. 1992 Biochemical assessment of bone loss in patients on long-term thyroid hormone treatment. Bone Miner 17:377-388.
41. Lehmke J, Bogner U, Felsenberg D, Peters H, Schleusener H. 1992 Determination of BMD by quantitative computed tomography and single photon absorptiometry in subclinical hyperthyroidism: a risk of early osteopaenia in postmenopausal women. Clin Endocrinol (Oxf) 36:511-517.
42. Mikosch P, Jauk B, Gallowitsch HJ, Pipam W, Kresnik E, Lind P. 2001 Suppressive levothyroxine therapy has no significant influence on bone degradation in women with thyroid carcinoma: a comparison with other disorders affecting bone metabolism. Thyroid 11:257-263.
43. Toivonen J, Tahtela R, Laitinen K, Risteli J, Valimaki MJ. 1988 Markers of bone turnover in patients with differentiated thyroid cancer with and following withdrawal of thyroxine suppressive therapy. Eur J Endocrinol 138:667-673.
44. Faber J, Galloe AM. 1994 Changes in bone mass during prolonged subclinical hyperthyroidism due to L-thyroxine treatment: a meta-analysis. Eur J Endocrinol 130:350-356.
45. Bauer DC, Nevitt MC, Ettinger B, Stone K. 1997 Low thyrotropin levels are not associated with bone loss in older women: a prospective study. J Clin Endocrinol Metab 82:2931-2936.
46. Fujiyama K, Kiriyama T, Ito M, et al. 1995 Suppressive doses of thyroxine do not accelerate age-related bone loss in late postmenopausal women. Thyroid 5:13-17.
47. Kung AW, Yeung SS. 1996 Prevention of bone loss induced by thyroxine suppressive therapy in postmenopausal women: the effect of calcium and calcitonin. J Clin Endocrinol Metab 81:1232-1236.
48. Campbell J, Day P, Diamond T. 1996 Fine adjustments in thyroxine replacement and its effect on bone metabolism. Thyroid 6:75-78.
49. Schneider DL, Barrett-Connor EL, Morton DJ 1994 Thyroid hormone use and BMD in elderly women. Effects of estrogen. JAMA 271:1245-1249.
50. Greenspan SL, Greenspan FS. 1999, The effect of thyroid hormone on skeletal integrity. Ann Intern Med 130:750-758.
51. Smith SR, Lovejoy JC, Rood J, et al. 2003 The effects of triiodothyronine on bone metabolism in healthy ambulatory men. Thyroid 13:357-364.
52. Sheppard MC, Holder R, Franklyn JA. 2002 Levothyroxine treatment and occurrence of fracture of the hip. Arch Intern Med 162:338-343.
53. Leese GP, Jung RT, Guthrie C, Waugh N, Browning MC. 1992 Morbidity in patients on L-thyroxine: a comparison of those with a normal TSH to those with a suppressed TSH. Clin Endocrinol (Oxf) 37:500-503.
54. Vestergaard P, Mosekilde L. 2002 Fractures in patients with hyperthyroidism and hypothyroidism: a nationwide follow-up study in 16,249 patients. Thyroid 12:411-419.
55. Cummings SR, Nevitt MC, Browner WS, et al. 1995 Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. N Engl J Med 332:767-773.
56. Bauer DC, Ettinger B, Nevitt MC, et al. 2001 Risk for fracture in women with low serum levels of thyroid-stimulating hormone. Ann Intern Med 134:561-568.
57. Gurlek A, Gedik O. 1999 Effect of endogenous subclinical hyperthyroidism on bone metabolism and BMD in premenopausal women. Thyroid 9:539-543.
58. Kumeda Y, Inaba M, Tahara H, et al. 2000 Persistent increase in bone turnover in Graves' patients with subclinical hyperthyroidism. J Clin Endocrinol Metab 85:4157-4161.
59. Faber J, Jensen IW, Petersen L, et al. 1998 Normalization of serum thyrotrophin by means of radioiodine treatment in subclinical hyperthyroidism: effect on bone loss in postmenopausal women. Clin Endocrinol (Oxf) 48:285-290.
60. Mosekilde L, Eriksen EF, Charles P. 1990 Effects of thyroid hormones on bone and mineral metabolism. Endocrinol Metab Clin North Am 19:35-63.
61. Auwerx J, Bouillon R. 1986 Mineral and bone metabolism in thyroid disease: a review. Q J Med 60:737-752.
62. Gomez Acotto C, Schott AM, Hans D, Niepomniszcze H, Mautalen CA, Meunier PJ. 1998 Hyperthyroidism influences ultrasound bone measurement on the Os calcis. Osteoporos Int, 1998. 8(5):455-9.
63. Hennessey JV, Evaul JE, Tseng YC, Burman KD, Wartofsky L. 1986 L-thyroxine dosage: a reevaluation of therapy with contemporary preparations. Ann Intern Med 105:11-5.
64. Wartofsky L. 1991 Use of sensitive TSH assay to determine optimal thyroid hormone therapy and avoid osteoporosis. Annu Rev Med 42:341-345.
65. Watts NB. 1989 Use of a sensitive thyrotropin assay for monitoring treatment with levothyroxine. Arch Intern Med 149:309-312.
66. Pujol P, Daures JP, Nsakala N, Baldet L, Bringer J, Jaffiol C. 1996 Degree of thyrotropin suppression as a prognostic determinant in differentiated thyroid cancer. J Clin Endocrinol Metab 81:4318-4323.
67. Blackwell B. 1973 Drug therapy: patient compliance. N Engl J Med 289:249-252.
68. Cooper DS. 1988 Thyroid hormone and the skeleton: a bone of contention. JAMA 259:3175.
69. Vitale G, Fonderico F, Martignetti A, et al. 2001 Pamidronate improves the quality of life and induces clinical remission of bone metastases in patients with thyroid cancer. Br J Cancer 84:1586-1590.